These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2038 related articles for article (PubMed ID: 34497605)

  • 1. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
    Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
    Front Immunol; 2021; 12():693062. PubMed ID: 34497605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive analysis of a chemokine- and chemokine receptor family-based signature for patients with lung adenocarcinoma.
    Fan T; Liu Y; Liu H; Wang L; Tian H; Zheng Y; Zheng B; Xue L; Tan F; Xue Q; Gao S; Li C; He J
    Cancer Immunol Immunother; 2021 Dec; 70(12):3651-3667. PubMed ID: 33977344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profiles of immune infiltration in lung adenocarcinoma and their clinical significant: A gene-expression-based retrospective study.
    Chen G; Dong Z; Wu D; Chen Y
    J Cell Biochem; 2020 Nov; 121(11):4431-4439. PubMed ID: 32003059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive molecular analyses of a TNF family-based signature with regard to prognosis, immune features, and biomarkers for immunotherapy in lung adenocarcinoma.
    Zhang C; Zhang G; Sun N; Zhang Z; Zhang Z; Luo Y; Che Y; Xue Q; He J
    EBioMedicine; 2020 Sep; 59():102959. PubMed ID: 32853987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying an immunogenic cell death-related gene signature contributes to predicting prognosis, immunotherapy efficacy, and tumor microenvironment of lung adenocarcinoma.
    Li X; Zhang D; Guo P; Ma S; Gao S; Li S; Yuan Y
    Aging (Albany NY); 2024 Apr; 16(7):6290-6313. PubMed ID: 38575204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
    Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
    Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on B cell marker genes to predict prognosis and immunotherapy response in lung adenocarcinoma.
    Song P; Li W; Wu X; Qian Z; Ying J; Gao S; He J
    Cancer Immunol Immunother; 2022 Oct; 71(10):2341-2354. PubMed ID: 35152302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of immune-related gene signature predicting survival in the tumor microenvironment of lung adenocarcinoma.
    Zhao M; Li M; Chen Z; Bian Y; Zheng Y; Hu Z; Liang J; Huang Y; Yin J; Zhan C; Feng M; Wang Q
    Immunogenetics; 2020 Dec; 72(9-10):455-465. PubMed ID: 33188484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
    Zuo S; Wei M; Wang S; Dong J; Wei J
    Front Immunol; 2020; 11():1218. PubMed ID: 32714316
    [No Abstract]   [Full Text] [Related]  

  • 11. A Seven-Gene Signature with Close Immune Correlation Was Identified for Survival Prediction of Lung Adenocarcinoma.
    Zou X; Hu Z; Huang C; Chang J
    Med Sci Monit; 2020 Jul; 26():e924269. PubMed ID: 32613949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An ICD-Associated DAMP Gene signature predicts survival and immunotherapy response of patients with lung adenocarcinoma.
    Wu Y; Li K; Liang S; Lou X; Li Y; Xu D; Wu Y; Wang Y; Cui W
    Respir Res; 2023 May; 24(1):142. PubMed ID: 37259066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarcinoma.
    Wu J; Li L; Zhang H; Zhao Y; Zhang H; Wu S; Xu B
    Oncogene; 2021 Jul; 40(26):4413-4424. PubMed ID: 34108619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of an immune-related prognostic signature in lung adenocarcinoma.
    Sun S; Guo W; Wang Z; Wang X; Zhang G; Zhang H; Li R; Gao Y; Qiu B; Tan F; Gao Y; Xue Q; Gao S; He J
    Cancer Med; 2020 Aug; 9(16):5960-5975. PubMed ID: 32592319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microenvironment Analysis of Prognosis and Molecular Signature of Immune-Related Genes in Lung Adenocarcinoma.
    Ling B; Huang Z; Huang S; Qian L; Li G; Tang Q
    Oncol Res; 2021 Mar; 28(6):561-578. PubMed ID: 32471520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognosis and immunotherapy significances of a cancer-associated fibroblasts-related gene signature in lung adenocarcinoma.
    Luo Y; Zhang S; Xie H; Su Q; He S; Lei Z
    Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):51-61. PubMed ID: 38279482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
    Wu P; Zheng Y; Wang Y; Wang Y; Liang N
    J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
    Li B; Cui Y; Diehn M; Li R
    JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
    Wu C; Rao X; Lin W
    Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction and validation of a T cell proliferation regulator-related signature for predicting prognosis and immunotherapy response in lung adenocarcinoma.
    Chang W; Li H; Cheng Y; He H; Ou W; Wang SY
    Front Immunol; 2023; 14():1171145. PubMed ID: 37081889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 102.